Skip to content

Clinical trials

Thrombocythemia, Essential trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Thrombocythemia, Essential Country / region: China Clear all

11 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20161
20203
20212
20231
20244

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Active, not recruiting4
Recruiting4
Unknown status2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institute of Hematology & Blood Diseases Hospital, China2
Merck Sharp & Dohme LLC2
Hangzhou GluBio Pharmaceutical Co., Ltd.1
Incyte Corporation1
Nanfang Hospital, Southern Medical University1
PharmaEssentia1
Shandong University1
Xiamen Amoytop Biotech Co., Ltd.1
Zhenya Hong1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Thrombocythemia, Essential11
Myelodysplastic Syndromes3
Myeloproliferative Disorders3
Polycythemia Vera3
Primary Myelofibrosis3
Leukemia, Myeloid, Acute2
Anemia, Aplastic1
Anemia, Hemolytic, Autoimmune1
Hemoglobinuria, Paroxysmal1
Hemophilia A1

Trials

Showing 76 to 11 of 11. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.